Tag: Drug Pipeline

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…

ME Desk